Ryan Deschner
Stock Analyst at Raymond James
(4.74)
# 94
Out of 5,180 analysts
19
Total ratings
77.78%
Success rate
52.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Upgrades: Strong Buy | $92 → $143 | $128.00 | +11.72% | 2 | Nov 19, 2025 | |
| TVRD Tvardi Therapeutics | Downgrades: Market Perform | n/a | $2.92 | - | 2 | Oct 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $38.26 | +7.16% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $12.21 | +121.13% | 3 | Aug 8, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $6.15 | +95.12% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $40.40 | +23.78% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $33.41 | +265.16% | 1 | Jul 24, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $8.01 | +249.56% | 3 | Jan 14, 2025 |
Palvella Therapeutics
Nov 19, 2025
Upgrades: Strong Buy
Price Target: $92 → $143
Current: $128.00
Upside: +11.72%
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.92
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $38.26
Upside: +7.16%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $12.21
Upside: +121.13%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $6.15
Upside: +95.12%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $40.40
Upside: +23.78%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $33.41
Upside: +265.16%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $8.01
Upside: +249.56%